
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
Summary Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA …